@FierceMedDev: Edwards' recall gets FDA's 'deadly' label as problems pile up. Story | Follow @FierceMedDev
@MarkHFierce: CardioDx set the terms for its IPO, upping the range. More | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce
> Endo Health Solutions ($ENDP) said that its sales of women's health products in the 2013 third quarter dipped, in part, because of controversies regarding vaginal mesh implants. But sales of men's health continence devices increased by a healthy margin. Item
> Bloomberg reports on the artificial pancreas and how various companies are faring in its development. Story
> Avedro of Waltham, MA, obtained a CE mark for its KXL II system, a nonsurgical device designed to correct myopia and improve cataract surgery outcomes. Item
> OrSense gained FDA clearance for a new noninvasive hemoglobin and pulse oximetry monitor. Item
> Provista Diagnostics has licensed biomarker technologies developed at Arizona State University focused on early detection of the human papillomavirus, plus breast and ovarian cancers. Story
> Wall Street liked the results of an Intuitive Surgical ($ISRG) study comparing its da Vinci surgical robot with open surgery and video-assisted thoracic surgery in treating patients with lung cancer. Story
Biotech News
@FierceBiotech: ImmunoGen scuttles lead PhII armed-antibody trial after tracking infection risk. More | Follow @FierceBiotech
@JohnCFierce: Novartis chopping 371 research jobs in global R&D reorganization. Goodbye, Horsham. Article | Follow @JohnCFierce
@DamianFierce: EW's long-running misfortunes continue with a Class I recall of a bypass device. Story | Follow @DamianFierce
> Midatech bags $16M round to back PhIIa studies on oral insulin program. More
> Analyst lays out 'doomsday scenario' for federal probe of AstraZeneca's Brilinta. Story
> Keryx jumps as kidney drug impresses in PhII, promises wider label. Article
Pharma News
@FiercePharma: Monday's top special report: Top 10 Drug Patent Losses 2014. Report | Follow @FiercePharma
@CarlyHFierce: ICYMI: J&J to pay $2.2B to wrap up long-standing Risperdal marketing probe. Story | Follow @CarlyHFierce
> Teva's ex-CEO reportedly forced polygraph tests on board to plug media leaks. More
> Novartis eyes animal health sale as first slim-down move: Bloomberg. Story
> Analyst's worst-case on Brilinta probe? Feds force AstraZeneca blood thinner off market. Article
Pharma Manufacturing News
> Merck to give pink slips to 500 West Point workers this holiday season. More
> PwC warns quality failings could slow growth of Indian biopharma. Story
> Developer pitches plan for Boston R&D and manufacturing complex. News
> Stalling biosimilars give Roche confidence to reopen Genentech plant. Report
> Novartis puts OTC unit and its troubled plant on second tier of sale priorities. Item
> FDA outlines plan to incentivize high-quality manufacturing. Article
Biotech Research News
@EmilyMFierce: Fewer NIH grants affected by sequestration than initially projected. Item | Follow @EmilyMFierce
> Survey details impact of federal cuts, sequestration on scientific research. More
> Key HIV protein structure revealed. Story
> Prana compound restores learning, memory loss in mice. Article
> Sage molecule could treat a wide range of CNS disorders. Report
> Study: Genetics drive neurocognitive decline in aging. More